MedTrace Logo

Tumor Molecular Profiling in Patients With Prostate Cancer

NCT05573789 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 220

Last updated 2022-10-19

No results posted yet for this study

Summary

The aim of the study was to evaluate the prevalence, the prognostic and predictive value of gene alterations in unselected patients with prostate cancer. Patients with histologically confirmed prostate cancer, treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments, were included. The presence of gene alterations was assessed using the ForeSENTIA® Prostate panel developed by NIPD Genetic.

Conditions

Interventions

GENETIC

Tumor molecular profiling

Tumor molecular profiling was assessed using the ForeSENTIA® Prostate panel developed by NIPD Genetic

Sponsors & Collaborators

  • NIPD Genetics

    collaborator UNKNOWN

  • Hellenic Cooperative Oncology Group

    lead OTHER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2020-12-31
Completion
2022-09-01

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05573789 on ClinicalTrials.gov